(PRQR) ProQR Therapeutics N.V. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRQR) ProQR Therapeutics N.V. Complete Analysis Pack
Download Your Competitive Advantage
This ProQR Therapeutics N.V. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the actual analysis, not just marketing text. Buy the full version to access the complete ready-to-use report.
Stars
No approved product
By end-2025, ProQR Therapeutics N.V. had no approved or marketed therapy, so none of its assets met the BCG "star" test of high share in a growing market. The portfolio still centered on development-stage programs, which means cash burn and clinical readouts mattered more than sales scale. That leaves no true Stars in the matrix.
No market-leading brand
ProQR Therapeutics N.V. had no market-leading brand in 2025 because it still had no approved RNA medicine or ophthalmology product, so commercial share stayed effectively 0%. Its closest assets, including its lead programs, were still in clinical development, not sales. That kept the Stars bucket empty and left value tied to pipeline readouts, not brand power.
No recurring product sales
ProQR still had 0 recurring product sales from an approved drug, so it did not have the revenue base a Star needs to scale in a fast market. Its FY2025 value was still tied to pipeline execution, not commercial demand, and that keeps the BCG profile closer to a development story than a sales franchise.
No commercial base-editing asset
ProQR Therapeutics N.V.’s Axiomer was proprietary in FY2025, but it was still a pre-commercial platform, so it did not yet meet BCG "star" criteria. Without marketed sales, share, or revenue, the asset was better viewed as a strategic option than a cash-generating leader. Platform strength alone does not create star status.
- Proprietary, but not sold yet
- Strategic option, not a Star
Star candidates still in development
Sepofarsen, Ultevursen, and Axiomer were ProQR Therapeutics N.V.'s main growth bets, but by end-2025 they still had no approved product revenue, so none had crossed into a true BCG star. The assets remained tied to clinical readouts and regulatory steps, which kept their upside high but execution risk high too.
As of the latest 2025 reporting, ProQR Therapeutics N.V. still depended on pipeline value, not commercial sales, to support these programs. That fits a "question mark" profile: strong promise, but not yet proven demand or cash flow.
- Sepofarsen: clinical risk stayed high
- Ultevursen: no end-2025 star status
- Axiomer: platform value, still unproven
- No approved sales by end-2025
ProQR Had No Stars in FY2025: Zero Revenue, Zero Approved Products
By end-2025, ProQR Therapeutics N.V. had no approved product, so it had no true BCG "Stars." Its lead assets were still clinical-stage, with 0 product revenue and no commercial share to support star status.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Product revenue | 0 |
| Star assets | None |
What is included in the product
Detailed Word Document
BCG view of ProQR Therapeutics’ pipeline: where to invest, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page ProQR Therapeutics N.V. BCG Matrix for fast portfolio clarity and decision-making
Reference Sources
Provides a credible source trail for ProQR Therapeutics N.V., helping validate key claims and support faster, better decisions.
Cash Cows
No approved revenue generator
ProQR Therapeutics N.V. had no approved commercial product in 2025, so it had nothing to milk for stable cash flow. Cash cows need a mature, low-growth market and a high share position, and that setup was absent here. The company reported no product sales in 2025, while cash, cash equivalents, and marketable securities were about $97 million at year-end, showing it still relied on financing, not cash generation.
No mature royalty franchise
ProQR Therapeutics N.V. had no mature royalty franchise: royalty income from marketed drugs was 0, and partner funding stayed tied to research and development, not a steady product line. In 2025, that meant no classic cash cow to fund growth, only collaboration cash for pipeline work. So the business remained a development-stage story, not a royalty-driven one.
No low-growth brand leader
ProQR Therapeutics N.V. had no commercialized pipeline asset in its latest reporting, so there was no low-growth brand leader to classify as a cash cow. With no product revenue to harvest, the Company was still funding research and development instead of collecting mature cash flows. That means this BCG box stayed empty in revenue terms.
Partner cash not a product cow
ProQR Therapeutics N.V.’s Eli Lilly, Ionis, Radboud, Inserm, and LUMC ties can bring non-dilutive cash, but that cash is contract- and milestone-based, not driven by a mature product. In the latest reported period, ProQR still had 0 approved commercial products, so these receipts are support funding, not a BCG cash cow.
- Milestone cash, not repeat sales
- 5 key collaboration partners
- No mature brand or product annuity
Cash cow absent
ProQR Therapeutics N.V. had no true cash cow in 2025: the balance sheet still relied on financing rounds and collaboration receipts, not steady operating cash generation. That is a very different profile from a mature unit funding the rest of the business.
End-2025 still looked pre-cow, with cash tied to external capital and deal economics rather than self-funding operations.
No recurring operating cash surplus.
Funding came from financing and collaborations.
2025 was still pre-cow.
ProQR Had No Cash Cow in 2025
ProQR Therapeutics N.V. had no cash cow in 2025. It had no approved product, no product sales, and no royalty stream, so there was no mature unit generating steady cash. Year-end cash, cash equivalents, and marketable securities were about $97 million, which still pointed to financing support, not self-funded operations.
| Cash Cow Check | 2025 |
|---|---|
| Approved products | 0 |
| Product sales | $0 |
| Year-end cash | $97M |
Preview Before You Purchase
ProQR Therapeutics N.V. Reference Sources
This preview shows the exact ProQR Therapeutics N.V. BCG Matrix report you’ll receive after purchase. No demo pages, no watermarks—just the full, ready-to-use document. Download it instantly and use it for analysis, presentations, or strategic planning. What you see here is the real file.
Dogs
No dead commercial franchise
ProQR Therapeutics N.V. had no legacy marketed product, so there was no revenue-generating franchise with low growth and weak share to classify as a Dog. The company’s latest reported results still centered on R&D, not a mature commercial asset, which fits a pipeline-stage profile rather than a stagnant cash trap. In BCG terms, that means no dead commercial franchise was visible.
No divestiture-ready brand
ProQR had no divestiture-ready brand in FY2025: it reported no product sales and kept value tied to pipeline programs, not a mature franchise. That leaves the classic Dog bucket empty. The company ended 2025 with cash and cash equivalents of about $78 million, while R&D expense stayed the main use of capital.
No mature low-return unit
ProQR Therapeutics N.V. had no mature low-return "Dog" unit because its portfolio was still centered on R&D programs, not on weak commercial products. A Dog in BCG terms needs both low growth and low share, and ProQR was mostly not yet commercial at all. So the mix looked like pipeline risk, not an underperforming legacy business.
No stranded manufacturing franchise
ProQR Therapeutics N.V. was not carrying a large, obsolete factory or distribution network, so this is not a classic "cash-trap" Dog. In its FY2025 development-stage model, the real risk was clinical failure in RNA-editing programs, not legacy operations or stranded inventory. That keeps capital tied to R&D, not to underused plants or old product lines.
- No obsolete manufacturing base
- Risk sat in trials, not legacy assets
- Lower chance of a stranded cash trap
Dogs not evident
As of end-2025, ProQR Therapeutics N.V. had no approved assets and no mature, revenue-generating products, so the BCG "Dogs" bucket was effectively empty. The issue was pipeline risk, not weak legacy cash cows: the company remained a development-stage RNA therapy story with speculative programs rather than obsolete ones. No commercial sales meant the quadrant reflected absence of approvals, not a cleanup of declining assets.
- No approved products at FY2025 end
- No mature legacy asset drag
- Pipeline remained clinical/speculative
- Dog quadrant effectively empty
ProQR’s FY2025 Dogs Bucket Stays Empty as Sales Remain Zero
ProQR Therapeutics N.V. had no FY2025 Dog asset because it reported no product sales and no approved commercial product. The business stayed R&D-led, with cash and cash equivalents of about $78 million at year-end 2025. So the BCG Dogs bucket was effectively empty.
| FY2025 metric | Value |
|---|---|
| Product sales | $0 |
| Cash and cash equivalents | ~$78M |
| Approved products | 0 |
Question Marks
Sepofarsen, Phase II/III
Sepofarsen was ProQR Therapeutics N.V.'s lead ophthalmology asset for LCA10, a rare CEP290-linked disease with an estimated 20,000-30,000 patients worldwide. It had no approved product share and no revenue, but sat in a high-need niche where even small efficacy gains could matter. That mix of big unmet need and zero market share is classic Question Mark.
Ultevursen, Phase II/III
Ultevursen in Phase II/III was a clear Question Mark: it targeted USH2A-mediated retinitis pigmentosa and Usher syndrome, where unmet need is high, but ProQR Therapeutics N.V. still had zero commercial share because it had no approval. The asset could only move up the matrix if late-stage data and regulators turned decisively positive. Until then, its value stayed tied to binary clinical risk, not sales.
Axiomer platform
Axiomer was ProQR Therapeutics N.V.'s proprietary RNA base-editing platform, and it stayed a Question Mark because it was still non-commercial and had 0 approved programs. The RNA-editing field is high growth, but ProQR’s platform share was still emerging in FY2025, so value depended on clinical proof, not sales. Until it turns pipeline wins into approved therapies, Axiomer remains a capital-intensive bet with uncertain market share.
Eli Lilly liver and CNS pact
ProQR Therapeutics N.V.’s Eli Lilly pact pushed it beyond eye disease into liver and CNS targets, adding exposure to a high-growth genetic-medicine field. The deal was still early stage: ProQR had no marketed product, and value depended on research success, not sales. Lilly’s collaboration also signaled scale, with up to $1.5 billion in potential milestones plus royalties.
- Broadened ProQR beyond retina
- Targeted liver and CNS disease
- No approved product yet
- Still an investment-phase bet
University and Ionis licenses
ProQR Therapeutics N.V.’s licenses with Radboud University Medical Center, Inserm, Ionis, and Leiden University Medical Center were discovery-stage bets, so they had low market share by definition. They fit the question mark bucket because their value only scales if ProQR turns them into approved drugs, backed by clinical data and partner milestones.
In 2025, ProQR’s model still depended on R&D spend and external validation, not sales from these assets. Until one license shows human proof and regulatory progress, they stay high-risk, high-upside options.
- Early-stage licensed assets
- Low market share, no sales
- Value tied to drug approval
- Clinical proof is the key trigger
ProQR’s Question Marks: High-Risk Bets, Big Upside
In FY2025, ProQR Therapeutics N.V.’s Question Marks stayed pre-revenue bets: Sepofarsen, Ultevursen, Axiomer, and early partner assets all had zero approved sales and depended on clinical wins, not market share. The Lilly pact added scale, with up to $1.5 billion in milestones plus royalties, but value still hinged on trial data and approval.
| Asset | FY2025 status | Question Mark driver |
|---|---|---|
| Sepofarsen | No revenue | High unmet need, zero share |
| Ultevursen | Phase II/III | Late-stage risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.